Modulation of aldosterone levels by -344 C/T CYP11B2 polymorphism and spironolactone use in resistant hypertension

Journal of the American Society of Hypertension

Volumn 8, Issue 3, 2014, Pages 146-151

  Fontana, Vanessa ^a   De Faria, Ana Paula Cabral ^a   Barbaro, Natália Ruggeri ^a   Sabbatini, Andréa Rodrigues ^a   Modolo, Rodrigo ^a   Lacchini, Riccardo ^b   Moreno, Heitor ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

aldosterone synthase and aldosterone breakthrough; Mineralocorticoid receptor antagonists; refractory hypertension

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADULT; ALDOSTERONE BLOOD LEVEL; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEART LEFT VENTRICLE MASS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE;

ALDOSTERONE SYNTHASE AND ALDOSTERONE BREAKTHROUGH; MINERALOCORTICOID RECEPTOR ANTAGONISTS; REFRACTORY HYPERTENSION;

AGED; ALDOSTERONE; ALDOSTERONE SYNTHASE; ALLELES; BLOOD PRESSURE; DNA; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POLYMORPHISM, GENETIC; SPIRONOLACTONE;

EID: 84896096148     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2013.12.001     Document Type: Article

References (31)

1. He BJ, Anderson ME. Aldosterone and cardiovascular disease: the heart of the matter. Trends Endocrinol Metab 2013;24:21-30.
2. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006;98:121-8. (Pubitemid 43902687)
3. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Int Med 2009;150:776-83.
4. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004;351:33-41.
5. Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, London GM, et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997;10:1326-34. (Pubitemid 28078735)
6. de Faria AP, Demacq C, Figueiredo VN, Moraes CH, Santos RC, Sabbatini AR, et al. Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension. Hypertens Res 2013;36:1067-72.
7. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-19.
8. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Int Med 2008;168: 1159-64. (Pubitemid 351831398)
9. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010;55:147-52.
10. Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC, Martins LC, Ferreira-Melo S, Coelho OR, et al. Aldosterone excess or escape: Treating resistant hypertension. J Clin Hypertens (Greenwich) 2009;11:245-52.
11. Takeuchi F, Yamamoto K, Katsuya T, Sugiyama T, Nabika T, Ohnaka K, et al. Reevaluation of the association of seven candidate genes with blood pressure and hypertension: a replication study and meta-analysis with a larger sample size. Hypertens Res 2012;35: 825-31.
12. Sookoian S, Gianotti TF, Gonzalez CD, Pirola CJ. Association of the C-344T aldosterone synthase gene variant with essential hypertension: a meta-analysis. J Hypertens 2007;25:5-13. (Pubitemid 44885657)
13. Davies E, Holloway CD, Ingram MC, Inglis GC, Friel EC, Morrison C, et al. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999;33: 703-7. (Pubitemid 29091652)
14. Alvarez-Madrazo S, Mackenzie SM, Davies E, Fraser R, Lee WK, Brown M, et al. Common polymorphisms in the CYP11B1 and CYP11B2 genes: evidence for a digenic influence on hypertension. Hypertension 2013;61:232-9.
15. Trenkel S, Seifarth C, Schobel H, Hahn EG, Hensen J. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Exp Clin Endocrinol Diabetes 2002;110:80-5. (Pubitemid 34296857)
16. Drager LF, Genta PR, Pedrosa RP, Nerbass FB, Gonzaga CC, Krieger EM, et al. Characteristics and predictors of obstructive sleep apnea in patients with systemic hypertension. Am J Cardiol 2010;105:1135-9.
17. Kathiresan S, Larson MG, Benjamin EJ, Corey D, Murabito JM, Fox CS, et al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens 2005;18: 657-65. (Pubitemid 40692433)
18. Lacchini R, Sabha M, Coeli FB, Favero FF, Yugar-Toledo J, Izidoro-Toledo TC, et al. T allele of -344 C/T polymorphism in aldosterone synthase gene is not associated with resistant hypertension. Hypertens Res 2009;32:159-62.
19. Barbato A, Russo P, Siani A, Folkerd EJ, Miller MA, Venezia A, et al. Aldosterone synthase gene (CYP11B2) C-344T polymorphism, plasma aldosterone, renin activity and blood pressure in a multi-ethnic population. J Hypertens 2004;22:1895-901. (Pubitemid 39336672)
20. Bassett MH, Zhang Y, Clyne C, White PC, Rainey WE. Differential regulation of aldosterone synthase and 11beta-hydroxylase transcription by steroidogenic factor-1. J Mol Endocrinol 2002;28:125-35. (Pubitemid 34428762)
21. Figueiredo VN, Yugar-Toledo JC, Martins LC, Martins LB, de Faria AP, de Haro Moraes C, et al. Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure. Blood Press 2012;21:31-8.
22. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, et al. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens 2011;25:532-8.
23. de Haro Moraes C, Figueiredo VN, de Faria AP, Barbaro NR, Sabbatini AR, Quinaglia T, et al. High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension. J Hum Hypertens 2013;27:225-30.
24. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40:892-6. (Pubitemid 35434912)
25. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, et al. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension 2008;51:339-44. (Pubitemid 351159948)
26. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-30. (Pubitemid 37315491)
27. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007;3:486-92. (Pubitemid 47313030)
28. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-6. (Pubitemid 36548598)
29. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 2012;18:1429-33.
30. Gros R, Ding Q, Liu B, Chorazyczewski J, Feldman RD. Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation. Am J Physiol Cell Physiol 2013;304:C532-40.
31. Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J, et al. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 2011; 57:442-51.